188 related articles for article (PubMed ID: 20231618)
1. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.
Rao UN; Lee SJ; Luo W; Mihm MC; Kirkwood JM
Am J Clin Pathol; 2010 Apr; 133(4):646-53. PubMed ID: 20231618
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
[TBL] [Abstract][Full Text] [Related]
4. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
Rao UN; Ibrahim J; Flaherty LE; Richards J; Kirkwood JM
J Clin Oncol; 2002 Apr; 20(8):2053-7. PubMed ID: 11956265
[TBL] [Abstract][Full Text] [Related]
5. Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients.
Tas F; Erturk K
Cancer Invest; 2017 Sep; 35(8):501-505. PubMed ID: 28799813
[TBL] [Abstract][Full Text] [Related]
6. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Melanoma Using Pathologic Features Identified by Natural Language Processing.
Yang J; Lian JW; Chin YH; Wang L; Lian A; Murphy GF; Zhou L
JAMA Netw Open; 2021 Sep; 4(9):e2126337. PubMed ID: 34550383
[TBL] [Abstract][Full Text] [Related]
9. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
10. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.
Mihm MC; Clemente CG; Cascinelli N
Lab Invest; 1996 Jan; 74(1):43-7. PubMed ID: 8569196
[TBL] [Abstract][Full Text] [Related]
11. Association between tumor-infiltrating lymphocytes and sentinel lymph node positivity in thin melanoma.
Santos FMD; Silva FCD; Pedron J; Furian RD; Fortes C; Bonamigo RR
An Bras Dermatol; 2019; 94(1):47-51. PubMed ID: 30726463
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes.
Grotz TE; Vaince F; Hieken TJ
Melanoma Res; 2013 Apr; 23(2):132-7. PubMed ID: 23344159
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Ren M; Dai B; Kong YY; Lv JJ; Cai X
Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
[TBL] [Abstract][Full Text] [Related]
16. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E; Roßner J; Aung TN; Rimm DL; Niessner H; Keim U; Serna-Higuita LM; Bonzheim I; Kuhn Cuellar L; Westphal D; Steininger J; Meier F; Pop OT; Forchhammer S; Flatz L; Eigentler T; Garbe C; Röcken M; Amaral T; Sinnberg T
EBioMedicine; 2023 Jul; 93():104644. PubMed ID: 37295047
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.
Azimi F; Scolyer RA; Rumcheva P; Moncrieff M; Murali R; McCarthy SW; Saw RP; Thompson JF
J Clin Oncol; 2012 Jul; 30(21):2678-83. PubMed ID: 22711850
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.
Park CK; Kim SK
Oncotarget; 2017 Feb; 8(9):14759-14769. PubMed ID: 28107203
[TBL] [Abstract][Full Text] [Related]
20. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
Agarwala SS; Lee SJ; Yip W; Rao UN; Tarhini AA; Cohen GI; Reintgen DS; Evans TL; Brell JM; Albertini MR; Atkins MB; Dakhil SR; Conry RM; Sosman JA; Flaherty LE; Sondak VK; Carson WE; Smylie MG; Pappo AS; Kefford RF; Kirkwood JM
J Clin Oncol; 2017 Mar; 35(8):885-892. PubMed ID: 28135150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
